AR119741A1 - Formas en estado sólido - Google Patents

Formas en estado sólido

Info

Publication number
AR119741A1
AR119741A1 ARP200101439A ARP200101439A AR119741A1 AR 119741 A1 AR119741 A1 AR 119741A1 AR P200101439 A ARP200101439 A AR P200101439A AR P200101439 A ARP200101439 A AR P200101439A AR 119741 A1 AR119741 A1 AR 119741A1
Authority
AR
Argentina
Prior art keywords
peaks
fluoro
methyl
compound
hydrochloride salt
Prior art date
Application number
ARP200101439A
Other languages
English (en)
Spanish (es)
Inventor
Stephan D Parent
Mary Chaves
Ron C Kelly
Prashant Agarwal
Darren Leonard Reid
Roman Shimanovich
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR119741A1 publication Critical patent/AR119741A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ARP200101439A 2019-05-21 2020-05-21 Formas en estado sólido AR119741A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962851049P 2019-05-21 2019-05-21

Publications (1)

Publication Number Publication Date
AR119741A1 true AR119741A1 (es) 2022-01-05

Family

ID=71016701

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101439A AR119741A1 (es) 2019-05-21 2020-05-21 Formas en estado sólido

Country Status (10)

Country Link
US (1) US12252486B2 (cg-RX-API-DMAC7.html)
EP (1) EP3972972A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022532790A (cg-RX-API-DMAC7.html)
AR (1) AR119741A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020277398B2 (cg-RX-API-DMAC7.html)
CA (1) CA3140394A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021014235A (cg-RX-API-DMAC7.html)
TW (1) TW202110836A (cg-RX-API-DMAC7.html)
UY (1) UY38711A (cg-RX-API-DMAC7.html)
WO (1) WO2020236948A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
EP3788053B1 (en) 2018-05-04 2024-07-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019217691A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Kras g12c阻害剤及びその使用方法
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
US12252486B2 (en) 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US20230183235A1 (en) * 2020-05-20 2023-06-15 Teva Pharmaceuticals International Gmbh Solid state forms of amg-510 and process for preparation thereof
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
JP2023551006A (ja) * 2020-11-26 2023-12-06 上▲海▼翰森生物医▲薬▼科技有限公司 窒素含有複素環誘導体の塩、結晶、並びにその調製方法、及び使用
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022246069A1 (en) 2021-05-19 2022-11-24 Teva Pharmaceuticals International Gmbh Process for preparation of sotorasib and solid state form thereof
CN114605406B (zh) * 2021-09-18 2023-05-26 都创(上海)医药开发有限公司 Amg510化合物的晶型及其制备方法和用途
CN115368358A (zh) * 2022-09-01 2022-11-22 浙江九洲药业股份有限公司 一种Sotorasib新晶型及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312059D0 (en) 2013-07-05 2013-08-21 Univ Leuven Kath Novel GAK modulators
MX380928B (es) 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Kras g12c阻害剤化合物の重要な中間体の改良合成法
US12252486B2 (en) 2019-05-21 2025-03-18 Amgen Inc. Solid state forms
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
EP4700030A3 (en) 2019-11-14 2026-03-18 Amgen, Inc. Improved synthesis of kras g12c inhibitor compound
CA3161156A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound

Also Published As

Publication number Publication date
UY38711A (es) 2020-11-30
AU2026200455A1 (en) 2026-02-12
JP2025131597A (ja) 2025-09-09
TW202110836A (zh) 2021-03-16
JP2022532790A (ja) 2022-07-19
MX2025010774A (es) 2025-10-01
AU2020277398B2 (en) 2026-01-29
US20220235045A1 (en) 2022-07-28
WO2020236948A1 (en) 2020-11-26
US12252486B2 (en) 2025-03-18
CA3140394A1 (en) 2020-11-26
MX2021014235A (es) 2022-03-11
AU2020277398A1 (en) 2021-12-09
EP3972972A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
AR118978A1 (es) Formas en estado sólido
MX2025010774A (es) Formas en estado solido
CA3261000A1 (en) PYRIDO[4,3-D]PYRIMIDINES COMPOUNDS
USD655592S1 (en) Four-jaw collet chuck
EP3980166A4 (en) CERAMIC ANION EXCHANGE MATERIALS
NO20043484L (no) 2-(pyridin-2-ylamino)-pyrido(2,3d)pyrimidin-7-on
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
EP4512483A3 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs thereof, and salts thereof and methods for their use in therapy
PE20142338A1 (es) Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf
GEP20186841B (en) Stabilized crystal of tipiracil hydrochloride, and crystallization method for same
EP3736068A4 (en) REVOLVING TOOL ROD OF A MACHINE TOOL
JP2017512803A5 (cg-RX-API-DMAC7.html)
IL275839B2 (en) Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
ES2531088T3 (es) Sales de clopidogrel y procedimiento de preparación
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
IL321492A (en) Single-cell methods for discovering disease resistance carriers
PL1861389T3 (pl) Sól, besylan 7-(2-(4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropiryd-1-ylo)etylo)izochinoliny, jej wytwarzanie i jej zastosowanie w lecznictwie
ZA200801813B (en) Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one
AR107167A1 (es) Forma cristalina de picoxistrobina, método de preparación y uso de esta
AR102804A1 (es) Formas sólidas de un modulador del canal iónico
ZA200302613B (en) Process for the preparation of bicyclic diketone salts.
FI3740190T3 (fi) Apomorfiini-palmitiinihappo-yhteiskiteen kiinteä hiukkasmainen kiteinen muoto
AR045362A1 (es) Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal